Advances with vaccination against Neisseria meningitidis

Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester, UK.
Tropical Medicine & International Health (Impact Factor: 2.33). 09/2012; 17(12). DOI: 10.1111/j.1365-3156.2012.03085.x
Source: PubMed


In the last decade, meningococcal serogroup C conjugate vaccination programs have been demonstrated to be hugely successful with a truly impressive public health impact. In sub-Saharan Africa, with the implementation of an affordable serogroup A conjugate vaccine, it is hoped that a similar public health impact will be demonstrated. Challenges still remain in the quest to develop and implement broadly protective vaccines against serogroup B disease. New, broad coverage vaccines against serogroup B are for the first time becoming available although little is known about their antibody persistence, effectiveness or effect on nasopharyngeal carriage. Enhanced surveillance following any potential vaccine introduction against serogroup B needs to be thoroughly implemented. The future now holds a distinct possibility, globally, for substantially decreasing meningococcal disease, regardless of infecting serogroup.
Au cours de la dernière décennie, les programmes de vaccination conjugués avec le méningocoque du sérogroupe C ont démontrés un énorme succès avec un impact véritablement impressionnant sur la santé publique. En Afrique subsaharienne, avec l’implémentation d’un vaccin conjugué du sérogroupe A à prix abordable, il est à espérer qu’un impact similaire sur la santé publique sera démontré. Les défis restent encore dans la quête pour développer et implémenter des vaccins à large protection contre la maladie due au sérogroupe B. De nouveaux vaccins avec une large couverture contre le sérogroupe B deviennent pour la première fois disponibles quoique peu soit connu sur la persistance de leurs anticorps, leur efficacité ou leur effet sur le portage nasopharyngé. Une surveillance accrue après toute introduction d’un vaccin potentiel contre le sérogroupe B devrait être sérieusement implémentée. L’avenir nous réserve maintenant une possibilité distincte, globalement, pour diminuer sensiblement la méningococcie, quel que soit le sérogroupe infectant.
Durante la última década, se ha demostrado que los programas de vacunación con la vacuna meningocócica conjugada frente al serogrupo C han sido muy exitosos, con un impacto en salud pública realmente impresionante. En África subsahariana, con la implementación de una vacuna conjugada frente al serogrupo A y asequible, se espera demostrar un impacto similar en salud pública. Los retos continúan en la búsqueda del desarrollo e implementación de vacunas que confieran protección amplia contra la enfermedad causada por el serogrupo B. Nuevas vacunas, con una amplia cobertura frente al serogrupo B, comienzan a estar disponibles por primera vez, aunque se conoce poco sobre la persistencia de anticuerpos y la efectividad o el efecto sobre los portadores nasofaríngeos. Es necesario implementar una vigilancia mejorada tras la introducción de cualquier vacuna potencial contra el serogrupo B. En el futuro ahora se vislumbra una posibilidad clara, a nivel global, de una disminución sustancial de la enfermedad meningocócica, independientemente del serogrupo.

Download full-text


Available from: Ray Borrow, Sep 15, 2014
11 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine (ACWY), utilising tetanus toxoid (TT) as its carrier protein (ACWY-TT; Nimenrix™, GlaxoSmithKline Vaccines, Rixensart, Belgium) has been demonstrated to be safe and immunogenic when administered to young children from 12 months of age, older children, adolescents, and adults. Administration of a single dose of ACWY-TT induces protective serum bactericidal antibodies against all four serogroups as well as good antibody persistence. Coadministration studies have demonstrated that ACWY-TT can be administered with diphtheria, tetanus, three-component acellular pertussis, hepatitis B, inactivated polio virus and Haemophilus influenzae type b conjugate vaccine (DTaP3-IPV-HBV/Hib, Infanrix™ hexa; GlaxoSmithKline Vaccines, Rixensart, Belgium); measles, mumps, rubella, varicella vaccine (Priorix-Tetra™; GlaxoSmithKline Vaccines, Rixensart, Belgium); 10-valent pneumococcal conjugate vaccine (Synflorix(®); GlaxoSmithKline Vaccines, Rixensart, Belgium); hepatitis A and B vaccine (Twinrix(®); GlaxoSmithKline Vaccines, Rixensart, Belgium); and seasonal influenza vaccine (Fluarix™; GlaxoSmithKline Vaccines, Rixensart, Belgium). Studies in young infants from 2 months of age have now commenced but immunisation with a single dose of ACWY-TT from 12 months of age is a safe and immunogenic option in the prevention of meningococcal disease.
    Advances in Therapy 05/2013; 30(5). DOI:10.1007/s12325-013-0032-5 · 2.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic. We obtained data for the incidence of meningitis before and after vaccination from national records between January, 2009, and June, 2012. In 2012, surveillance was enhanced in regions where vaccination with PsA-TT had been undertaken in 2011, and in one district where a reactive vaccination campaign in response to an outbreak of meningitis was undertaken. Meningococcal carriage was studied in an age-stratified sample of residents aged 1-29 years of a rural area roughly 13-15 and 2-4 months before and 4-6 months after vaccination. Meningococci obtained from cerebrospinal fluid or oropharyngeal swabs were characterised by conventional microbiological and molecular methods. Roughly 1·8 million individuals aged 1-29 years received one dose of PsA-TT during a vaccination campaign in three regions of Chad in and around the capital N'Djamena during 10 days in December, 2011. The incidence of meningitis during the 2012 meningitis season in these three regions was 2·48 per 100 000 (57 cases in the 2·3 million population), whereas in regions without mass vaccination, incidence was 43·8 per 100 000 (3809 cases per 8·7 million population), a 94% difference in crude incidence (p<0·0001), and an incidence rate ratio of 0·096 (95% CI 0·046-0·198). Despite enhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the three vaccinated regions. 32 serogroup A carriers were identified in 4278 age-stratified individuals (0·75%) living in a rural area near the capital 2-4 months before vaccination, whereas only one serogroup A meningococcus was isolated in 5001 people living in the same community 4-6 months after vaccination (adjusted odds ratio 0·019, 95% CI 0·002-0·138; p<0·0001). PSA-TT was highly effective at prevention of serogroup A invasive meningococcal disease and carriage in Chad. How long this protection will persist needs to be established. The Bill & Melinda Gates Foundation, the Wellcome Trust, and Médecins Sans Frontères.
    The Lancet 09/2013; 383(9911). DOI:10.1016/S0140-6736(13)61612-8 · 45.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive disease caused by Neisseria meningitidis is associated with high mortality and high disability rates and mainly affects children under one year of age. Vaccination is the best way to prevent meningococcal disease, especially in infants and toddlers. The introduction of massive meningococcal serogroup C vaccination has drastically reduced the incidence of disease caused by this serogroup, and serogroup B has now become the main causative agent in several industrialized countries. The first serogroup B vaccines, which were used for more than two decades, were based on outer membrane vesicles and proved to be protective only against specific epidemic strains in Cuba, Norway, Brazil and New Zealand. Moreover, these often elicited a scant immune response in young children. Innovative genomics-based reverse vaccinology subsequently enabled researchers to identify genes encoding for surface proteins that are able to elicit a strong immune response against several B strains. This important discovery led to the development and recent approval in Europe of the four-component meningococcal serogroup B (4CMenB) vaccine. Large clinical trials have shown high immunogenicity and tolerability and acceptable safety levels of 4CMenB in infants and toddlers. This vaccine is expected to cover a large number of circulating invasive strains and may also be efficacious against other serogroups. Young children are particularly vulnerable to the devastating consequences of meningococcal disease. Given the high performance of 4CMenB and its non-interference with routine vaccinations, this age-group will be the first to benefit from the introduction of this vaccine.
    The Indian Journal of Medical Research 12/2013; 138(6):835-46. · 1.40 Impact Factor
Show more